Brainstorm Cell Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Brainstorm Cell Therapeutics generated cash of -$20,458,000, which is less than the previous year. Cash used in financing activities reached the amount of $18,978,000 last year. Net change in cash is therefore $713,000.
Cash Flow
| 2014 | -4.48M | -4.45M | 9.68M |
|---|---|---|---|
| 2015 | -7.40M | -11.28M | 14.86M |
| 2016 | -5.85M | 5.97M | 0 |
| 2017 | -2.36M | 3.98M | 314K |
| 2018 | -12.38M | -1.21M | 12.06M |
| 2019 | -11.24M | 5.61M | 5.22M |
| 2020 | -35.19M | -4.45M | 76.93M |
| 2021 | -26.26M | 323K | 6.96M |
| 2022 | -19.32M | 998K | 238K |
| 2023 | -20.45M | 2.19M | 18.97M |
BCLI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 772K | 18.85M | 37.82M | 536K | 942K | 2.48M | 547K | 428K | 4.25M | 3.50M |
Operating activities | ||||||||||
Net income | -17.19M | -24.27M | -24.45M | -31.81M | -23.25M | -13.94M | -4.95M | -4.98M | -8.48M | -9.24M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 265K | 285K | 260K | 219K | 164K | 110K | 85K | 77K | 87K | 106K |
Stock-based compensation expense | 0 | 1.68M | 1.36M | 2.56M | 764K | 0 | 554K | 635K | 835K | 1.22M |
| Deferred income tax benefit | 0 | 1.68M | 1.36M | 2.56M | 764K | 0 | 554K | 635K | 835K | 1.22M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 1.06M | 335K | 1.49M | 690K | -238K | -2.79M | 379K | 204K | -93K |
Inventories | 0 | -1.06M | -335K | -1.49M | 0 | 0 | 975K | 0 | 212K | 467K |
Accounts payable | 0 | 2.52M | -1.71M | -9.26M | 10.12M | 3.12M | 1.07M | -824K | -373K | 1.31M |
Cash generated by operating activities | -20.45M | -19.32M | -26.26M | -35.19M | -11.24M | -12.38M | -2.36M | -5.85M | -7.40M | -4.48M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -4.07M | 0 | -849K | -4K | 0 | -11.23M | 0 |
Investments In Property Plant And Equipment | -18K | -29K | -330K | -378K | -473K | -369K | -180K | -103K | -45K | -161K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 2.19M | 998K | 323K | -4.45M | 5.61M | -1.21M | 3.98M | 5.97M | -11.28M | -4.45M |
Financing activities | ||||||||||
Common Stock Issued | 18.97M | 238K | 6.96M | 60.72M | 2.06M | 12.06M | 314K | 0 | 14.86M | 9.55M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -116K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 18.97M | 238K | 6.96M | 76.93M | 5.22M | 12.06M | 314K | 0 | 14.86M | 9.68M |
Net Change In Cash | 713K | -18.08M | -18.97M | 37.29M | -406K | -1.54M | 1.93M | 119K | -3.82M | 748K |
Cash at end of period | 1.48K | 772K | 18.85M | 37.82M | 536K | 942K | 2.48M | 547K | 428K | 4.25M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |